Take a look at our latest updates across different markets regarding launches, alliances, participations, events, expert opinions and more.
Our genomic test myChoice CDx Plus has been recognized by the ESGO-ESMO-ESP 2024 consensus with a Level of Evidence 1A.
Varifarma launched GORAX® (Relugolix) at the International Symposium “Advances in Urology 2024” organized by the Argentine Society of Urology.
We Launched Gorax (Relugolix) 120mg, the first LHRH antagonist with oral intake in Argentina.
Developed by Varifarma, Gorax is a revolutionary breakthrough in advanced prostate cancer treatment.
A new therapeutic alternative with multiple indications arrives to Varifarma!
We continue to increase our treatment options for our patients! We’re launching Tepadina 400mg.
Another year full of innovation, launches, and new options for patients. We celebrate a year of innovation and progress at Varifarma 2023: Launches that make a difference!
Within the framework of the congress, the 1st meeting of the Uruguayan Lymphoma Group (GULI) and the XVII Hemato-Oncological Nursing Workshops were held.
Explorando los avances pioneros en el tratamiento de la Leucemia Linfoblástica Aguda (LLA), Varifarma dió el presente en el reciente curso de la Sociedad Peruana de Hematología sobre Inmunoterapia con Blinatumomab. La destacada presentación de la Dra. Laura Garcia de México resaltó el papel fundamental de esta innovadora terapia y la importancia del perfilamiento preciso de los pacientes.
SUEM Workshop on Pituitary Pathology: Cushing and Acromegaly in Uruguay, with the presence of VARIFARMA and participation of distinguished experts.
We support the Argentine Society of Hematology in the continuous medical education of professionals.
